Trends of Stem Cell Therapies in Age-Related Macular Degeneration

被引：31

作者：

Maeda, Tadao ^{[1
,2
]}

Sugita, Sunao ^{[1
,2
]}

Kurimoto, Yasuo ^{[1
,2
]}

Takahashi, Masayo ^{[1
,2
]}

机构：

[1] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo 6500047, Japan

[2] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 08期

关键词：

regenerative medicine; retinal pigment epithelium; iPS cell; ES cell; stem cell; age-related macular degeneration; clinical trial; retina; immune reaction; transplantation;

D O I：

10.3390/jcm10081785

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Age-related macular degeneration (AMD) is a highly prevalent irreversible impairment in the elderly population worldwide. Stem cell therapies have been considered potentially viable for treating AMD through the direct replacement of degenerated cells or secretion of trophic factors that facilitate the survival of existing cells. Among them, the safety of pluripotent stem cell-derived retinal pigment epithelial (RPE) cell transplantation against AMD, and some hereditary retinal degenerative diseases, has been discussed to a certain extent in clinical studies of RPE cell transplantation. Preparations are in progress for its clinical application. On the other hand, clinical trials using somatic stem cells are also being conducted, though these had controversial outcomes. Retinal regenerative medicine using stem cells is expected to make steady progress toward practical use while new technologies are incorporated from various fields, thereby making the role of ophthalmologists in this field increasingly important.

引用

页数：20